logo-loader
RNS
GenIP PLC

GenIP PLC - New Orders

RNS Number : 1668F
GenIP PLC
21 May 2026
 

 




 

21 May 2026

 

GenIP Plc

("GenIP" or the "Company")

 

New Orders

GenIP Plc (AIM: GNIP), a technology consultancy providing AI-driven services to help research organisations and corporations commercialise their innovations, is pleased to announce the following new orders.

#1 Ranked Research University in Hong Kong

The Company has entered into a 12-month framework agreement with a leading Hong Kong research university, with an option to renew for a further 12 months. The agreement enables portfolio-level evaluations of up to 10 technologies per order, with orders placed by the university as required. The engagement is valued at approximately $20,000 per year, with potential for additional work beyond the initial scope.

Major UK Higher Education Institution

The Company has secured a first-time engagement with a well-established modern university in London, recognised for its strengths in applied research, engineering, and technology. The initial order covers 10 reports, with the likelihood of additional repeat orders to evaluate the institution's broad innovation portfolio.

South African Client: Invention Validator

A South African client has deployed the Company's recently launched Invention Validator product, representing one of the first engagements for this offering. The engagement is valued at approximately $14,500 for a single technology evaluation. The product is currently operating with a 60% margin floor, supporting strong unit economics as adoption scales.

Canadian and US Research Universities

The Company has secured its first Canadian client, one of Canada's leading research universities, with over 65,000 students and a strong international reputation in AI, engineering, health sciences, and technology research. The Company has also secured an engagement with one of North America's leading public research universities, internationally recognised for its programmes in engineering, AI, computer science, and technology innovation. Comparable institutions place orders monthly, and we are confident we'll maintain a similar relationship with our new clients.

The Company will announce their FY2025 results within the next two weeks and will include an outlook at that time.

Melissa Cruz, CEO of GenIP, commented:

"Securing a framework agreement with the #1 ranked university for patent influence in China is a major validation of our new AI-driven products.

 

More broadly, we are delighted with the response to our expanding range of products and believe GenIP is perfectly positioned for another year of top-line growth in 2026 as the number of long-term repeat customers grows."

 

 

For further information regarding GenIP, please visit www.genip.ai, or contact:

 

GenIP Plc

Melissa Cruz, CEO 


Via Redchurch Communications




Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish / Asia Szusciak / Andrew Price

 

 


Tel:  +44 (0) 20 7628 3396

 

AlbR Capital Limited (Joint Broker) 

Colin Rowbury

Jon Belliss

            

Tel: +44 (0)20 7399 9427

cr@albrcapital.com 

Jb@albrcapital.com

 

 

CMC Markets (Joint Broker)

Douglas Crippen 


Tel: + 44 (0) 203 003 8632

 



 

Redchurch Communications (Financial PR)

John Casey

 

 


genip@weareredchurch.com

 

 

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation business      at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

Service

Description

Value Proposition

Invention Intelligence Product Suite

AI-powered market intelligence reports assessing the commercial potential of emerging technologies

Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy

IP Commercialization Services

 

End-to-end engagement to help research organisations commercialise innovations

 

Provides cost-effective, broad support to achieve our clients' strategic objectives

 

 

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

 

●    Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

●    Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

●    Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTEAPSEADDKEFA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

6 min read